Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Thank you

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Feb 01, 2021 3:47pm

144 Views

Post# 32439297

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Thank you

Those research articles that you posted are very helpful and again why would the Kol s reccommend spending tens of millions in a trial if in fact there is a gaping hole,,,,They made a lousy deal and even an extremely lousy deal but IT IS NOT BECAUSE THERE IS A GAPING HOLE IN THE DATA.....

scarlet1967 wrote: I posted a couple of research articles published in 2021 emphasizing the role of insulin resistance, mitochondrial dysfunction, pro inflammatory proteins and adipose tissue in causation of NAFLD/NASH quite inline with company's proposed MOA of their protocol and they proved that on HIV liver which because of the virus and ART drugs has more fat deposition than normal liver so the holes might not be as sizeable as some suggested on the contrary the industry is moving away from fibrosis resolution to Nash score reduction as the anti fibrotic approaches have failed miserably to date.Just listen to discussions the KOLs had after FDA,s podcast last Friday, to me it sounded they want to move away from biopsies to none invasive methods and most are not happy with the current endpoints.

palinc2000 wrote: Whatever hole there is we know it is NOT a sink hole....I have not seen any subsequent studies since the decision to go for General Nash which has shown a worsening of the odds of success,,,On the contrary !!!!!
The decision was based on strong recommandations by Grinspoon and lLoomba and probably others .....They know what they have and they know what they dont have,,,,Why would they spend tens of millions if the data is so bad to start with....,,,,,

quote=scarlet1967]Paul said he is going to accelerate the process even so Jim doesn't agreed with me what I heard was he described the dosing and early data as upcoming milestones so my take is they will announce any progress as soon as possible now exactly when nobody knows not even the company but I am pretty sure they are eager to announce early news.
As per holes for NASH we can speculate the size of them and how much the valuation should be discounted but not to allocate any NPV to a phase 3 trial is not the way market values other R&D companies.
The problem is not the hole of the trial the problem is the massive hole in their marketing of the trial.